Table 2 Prognostic significance of PD-L1 and p53 expression levels, along with clinical variables, in the radically resected pLELC cohort (n = 47)
Variables | n (%) | Median DFS/months | P |
|---|---|---|---|
Age (mean ± SD, years) | 54.4 ± 8.8 | ||
Age | |||
<50 years | 13 (27.6) | 30.9 (15.6–46.2) | 0.665 |
≥50 years | 34 (72.4) | 32.3 (24.2–40.4) | |
Gender | |||
Female | 29 (61.7) | 32.3 (29.1–35.5) | 0.666 |
Male | 18 (38.3) | 25.6 (11.9–39.3) | |
Smoking | |||
Yes | 12 (25.5) | 25.6 (5.2–46.0) | 0.466 |
No | 35 (74.5) | 30.9 (27.4–34.4) | |
Family history of cancer | |||
Yes | 6 (12.8) | 45.7 (30.2–61.2) | 0.242 |
No | 41 (87.2) | 29.8 (19.7–40.0) | |
Clinical stage | |||
I | 19 (40.4) | 29.9 (11.4–48.3) | 0.185 |
II | 7 (14.9) | 18.1 (1.0–35.5) | |
IIIA | 21 (44.7) | 35.4 (15.3–55.5) | |
PD-L1 in tumor cells | |||
<1% | 18 (38.3) | 19.2 (16.4–22.0) | 0.020* |
1–49% | 17 (36.2) | 32.3 (19.6–45.0) | |
≥50% | 12 (25.5) | 57.6 (27.6–87.6) | |
p53 | |||
Wild type | 21 (44.7) | 45.1 (27.2–63.0) | 0.033* |
Mutation type | 26 (55.3) | 20.0 (3.2–36.7) |
